Evogene (EVGN) Common Equity (2011 - 2025)

Evogene has disclosed Common Equity across 15 years of filings, most recently posting $12.0 million for Q4 2025.

• In Q4 2025, Common Equity fell 19.3% year-over-year to $12.0 million; the TTM figure through Dec 2025 stood at $12.0 million (down 19.3% YoY), while the FY2025 annual figure was $12.0 million, down 19.3% from the prior year.
• Common Equity came in at $12.0 million for Q4 2025 at Evogene, down from $12.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $82.1 million in Q1 2021 to a low of $12.0 million in Q4 2025.
• Average Common Equity over 5 years is $36.1 million, with a median of $30.1 million recorded in 2021.
• Year-over-year, Common Equity surged 50.36% in 2021 and slumped 65.88% in 2024.
• Over 5 years, Common Equity stood at $30.4 million in 2021, then slipped by 1.97% to $29.8 million in 2022, then fell by 3.88% to $28.7 million in 2023, then slumped by 48.27% to $14.8 million in 2024, then slipped by 19.3% to $12.0 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $12.0 million in Q4 2025, $12.4 million in Q2 2025, and $14.8 million in Q4 2024.